Suppr超能文献

IgG4相关性疾病复发的危险因素:一项系统评价和荟萃分析。

Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.

作者信息

Yang Fan, Wang Tianqi, Liu Yanying

机构信息

Department of Rheumatology, Beijing Friendship Hospital, Capital Medical University, No.95 Yong'an Road, Xicheng District, Beijing, China.

出版信息

Clin Rheumatol. 2025 Aug 19. doi: 10.1007/s10067-025-07641-3.

Abstract

OBJECTIVES

Patients with IgG4-related disease (IgG4-RD) suffer high relapse during long-term treatment, but risk factors associated with relapse are not well established. This study aims to review the potential risk factors and integrate relapse rates of observational studies for IgG4-RD.

METHOD

Relevant articles published up to January 28, 2025, were comprehensively and systematically identified from PubMed, EMBASE, and Web of Science databases. A systematic review and meta-analysis was performed to estimate pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence interval (CI).

RESULTS

Twenty-four studies comprising 3797 patients were included. Our findings reveal that a history of allergies (OR: 2.97, 95%CI: 2.07-4.25, P < 0.001), multi-organ involvement (HR: 1.60, 95% CI: 1.23-2.09, P = 0.0005), and decreased complement levels (HR: 2.27, 95% CI: 1.04-4.93, P = 0.04) are significantly associated with relapse. Furthermore, the combination of corticosteroids and immunosuppressants significantly reduces relapse rates (HR: 0.25, 95% CI: 0.10-0.62, P = 0.003). The pooled 12-, 24-, and 36-month relapse rates were 17% (95% CI: 0.10-0.24), 26% (95% CI: 0.22-0.31) and 33% (95% CI: 0.26-0.39), respectively.

CONCLUSIONS

This meta-analysis indicated that a history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. Besides, corticosteroid combined with immunosuppressant therapy could decrease relapse rates. Key Points • A history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. • The combination of corticosteroids and immunosuppressants could reduces relapse rates of IgG4-RD. • The 12-, 24- and 36-month relapse rates of IgG4-RD were 17%, 26% and 33%, respectively.

摘要

目的

IgG4相关性疾病(IgG4-RD)患者在长期治疗期间复发率较高,但与复发相关的危险因素尚未完全明确。本研究旨在回顾潜在的危险因素,并汇总IgG4-RD观察性研究的复发率。

方法

从PubMed、EMBASE和Web of Science数据库中全面、系统地检索截至2025年1月28日发表的相关文章。进行系统评价和荟萃分析,以估计合并比值比(OR)、风险比(HR)和95%置信区间(CI)。

结果

纳入了24项研究,共3797例患者。我们的研究结果显示,过敏史(OR:2.97,95%CI:2.07-4.25,P<0.001)、多器官受累(HR:1.60,95%CI:1.23-2.09,P=0.0005)和补体水平降低(HR:2.27,95%CI:1.04-4.93,P=0.04)与复发显著相关。此外,糖皮质激素和免疫抑制剂联合使用可显著降低复发率(HR:0.25,95%CI:0.10-0.62,P=0.003)。汇总的12个月、24个月和36个月复发率分别为17%(95%CI:0.10-0.24)、26%(95%CI:0.22-0.31)和33%(95%CI:0.26-0.39)。

结论

这项荟萃分析表明,过敏史、多器官受累和补体水平降低是IgG4-RD复发的危险因素。此外,糖皮质激素联合免疫抑制剂治疗可降低复发率。要点•过敏史、多器官受累和补体水平降低是IgG4-RD复发的危险因素。•糖皮质激素和免疫抑制剂联合使用可降低IgG4-RD的复发率。•IgG4-RD的12个月、24个月和36个月复发率分别为17%、26%和33%。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验